Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The UK is in the midst of a wide-ranging national industrial strategy which will influence the country’s future role in the global economy. The latest proposals look at the life sciences and healthcare sectors, perhaps the areas of this grand plan which will affect most people, including through the successful development – or otherwise – of the National Health Service.

The Conversation logo

Sir John Bell was asked to work on how the UK might exploit its existing strengths in life sciences. His report issues the strong recommendation that research and development (R&D) spending should rise from 1.6% of GDP to 2.6% over the next five years – putting the UK in the top quartile worldwide.

He also wants the UK to create two or three entirely new industries in the next decade, while increasing by 50% the number of clinical trials, and attracting capital investment for large and small manufacturing facilities. The plan is for the UK to end up with four life sciences and pharmaceutical firms with a market value of over £20 billion, attracting a host of world-class scientists into the country.

Quite how this can be achieved in a post-Brexit landscape is perhaps a matter for another day, but these aims will certainly require strong foundations on which to build.

Read more....

Similar stories

Oxford BioEscalator celebrates three years of innovation

The BioEscalator concept was born out of a shared need by academic researchers and their bioscience company collaborators for start-up incubator space close to academic labs. The vision was to develop a leading international centre for innovative bioscience with the potential to make a significant impact on healthcare. The incubator provides spin-outs and start-ups with laboratory and business support, enabling them to grow into leading bioscience ventures.

Immunology and AI drug discovery partnership agreed with Sensyne Health

The University has signed an agreement with Sensyne Health to conduct a multi-omics drug discovery research project in asthma. The project will be led by Dr Timothy Hinks and his team at the Nuffield Department of Medicine’s Respiratory Medicine Unit.

Oxford overseas research facility expands to include diagnostics and genetics testing centre

The Oxford-Suzhou Centre for Advanced Research, known as OSCAR, has marked another significant milestone with the launch of OSCAR-Prenetics Innovation and Technology Centre for Advanced Molecular Diagnostics (the OSCAR-Prenetics ITC).

Oxford joins forces with 11 universities to launch social impact investment fund

The University of Oxford has joined forces with 11 leading universities to create Impact 12, an impact investment fund to support mission-led university ventures.

AIMday in Experimental Medicine in Psychiatry - registration for academics now open

Are you an academic interested in finding out how your knowledge can be used to solve industry challenges? Would you like to widen your network? Meet potential collaborators / future employees? Gain insights into relevant funding schemes? If you answer YES to any of the above, now is the time to register for the AIMday in Experimental Medicine in Psychiatry.

Innovation award for Professor Anindita Roy to develop new treatments for childhood cancer

Associate Professor Andi Roy leads one of the five research teams across the UK that have been awarded the 2021 Cancer Research UK-Children with Cancer UK Innovation Award. The awards, which provide a total of £4.3 million in scientific funding, will allow leading researchers in the field to delve into the biology of children’s and young people’s cancers, with the hope of finding new ways to prevent and treat these complex cancers.